Beyond A, B and O lies a hidden world of rare blood types. Researchers have finally pinned down the genetic source of one that eluded science since 1972 — a discovery that could save the lives of a tiny, hard-to-match group of patients.
With psychedelic therapies advancing toward the market, a public FDA hearing wrestled with a central tension: how to protect patients without building an approval system so restrictive that few can actually use them.
Bundibugyo virus, a lesser-known cousin of Ebola, has caused its largest outbreak on record in Central Africa — and there’s no licensed vaccine or treatment for it.
Thousands of clinical trials recruit at any moment, yet most eligible patients never join — and it’s usually not because they refuse. The bigger failure is an information system that buries the trials they’d qualify for.
A new electronic artificial urinary sphincter lets men restore bladder control at the push of a key-fob button — a potential upgrade over devices that require an awkward manual squeeze. Early results are promising, but the study is tiny.
IUD placement can hurt — and patients have long said so. A double-blind randomized trial found a lidocaine paracervical block reduced pain, especially for those who’ve never given birth.
The faith’s governing body will now permit members to accept the major blood components and blood-derived products, while maintaining its prohibition on whole-blood transfusions.
Interim results from a randomized trial suggest that halving the length of antibiotic treatment for surgically treated orthopedic infections doesn’t worsen outcomes — and causes fewer side effects.
In a 12-week pilot, people with early Huntington’s who confined eating to a daily window showed improvements in disease and nerve-damage markers — but with no control group, the researchers stress it’s far from proof.
Brenipatide belongs to the same class as tirzepatide — but it’s tuned for the brain. Early data have Lilly moving it straight into late-stage trials for alcohol use disorder and depression.
A major review confirms that exercise-based cardiac rehabilitation delivers lasting benefits after heart disease. The bigger problem, a companion review finds, is that most eligible patients never take part.
Some cells begin the self-destruct process, then abort it and go on to rebuild damaged tissue. The finding reveals a hidden engine of regeneration — and a possible clue to why some cancers come back stronger.